Lundbeck's VYEPTI Shows Improvement in Migraine-Related Cognitive Symptoms in Real-World INFUSE Study

Key Takeaways

• INFUSE study demonstrates real-world improvement in migraine-related cognitive symptoms with VYEPTI treatment over 6 months
• Study focused on patients who had failed at least one prior anti-CGRP treatment, representing a difficult-to-treat population
• Data presented at AAN 2026 reinforces VYEPTI’s effectiveness beyond traditional migraine frequency measures

---

Lundbeck Presents Positive VYEPTI Data at AAN 2026

H. Lundbeck A/S presented encouraging real-world data from its INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting on April 19, demonstrating improvements in migraine-related cognitive symptoms among patients treated with VYEPTI® (eptinezumab).

Study Details and Patient Population

The one-year INFUSE study tracked patient-reported migraine-related cognitive symptoms over six months in individuals who had experienced at least one prior anti-calcitonin gene-related peptide (anti-CGRP) treatment failure. This patient population represents a particularly challenging group to treat, as they had already shown inadequate response to other CGRP-targeted therapies.

The study’s focus on cognitive symptoms addresses a critical but often overlooked aspect of migraine burden. Many migraine patients experience “brain fog,” difficulty concentrating, and other cognitive impairments that can significantly impact daily functioning and quality of life.

Clinical Significance and Market Impact

These findings are particularly significant because they demonstrate VYEPTI’s effectiveness in a real-world setting among treatment-resistant patients. The data suggests that even patients who have failed other anti-CGRP treatments may still benefit from switching to eptinezumab.

VYEPTI, administered as a quarterly intravenous infusion, belongs to the newer class of CGRP inhibitors that have revolutionized migraine prevention. The drug’s ability to improve cognitive symptoms beyond traditional measures like headache frequency could strengthen its competitive position in the crowded migraine prevention market.

Implications for Treatment Guidelines

The INFUSE study results may influence clinical decision-making for neurologists treating patients with treatment-resistant migraines. The data supports the concept that patients shouldn’t give up on CGRP-targeted therapy after one failure, as different mechanisms within the class may yield varying responses.

Lundbeck’s continued investment in real-world evidence studies demonstrates the company’s commitment to understanding VYEPTI’s full therapeutic potential beyond controlled clinical trials.

---

Frequently Asked Questions

What does this mean for patients who failed other migraine treatments?

The INFUSE study suggests that patients who didn’t respond to other anti-CGRP treatments may still benefit from VYEPTI, particularly in improving cognitive symptoms like brain fog and concentration difficulties associated with migraines.

How is VYEPTI different from other migraine prevention drugs?

VYEPTI is administered as a quarterly IV infusion rather than daily pills or monthly injections. It’s a monoclonal antibody that blocks CGRP, and this study shows it may be effective even when other CGRP inhibitors have failed.

When will these study results impact treatment recommendations?

While the data was just presented at AAN 2026, neurologists may begin considering these findings immediately when treating patients with treatment-resistant migraines. Formal guideline updates typically take longer to incorporate new evidence.